克服转移性癌症中的化疗抵抗:综合性审查
Maryam Eslami1,2,3, Omid Memarsadeghi1,2, Ali Davarpanah1,2,3
1Applied Biotechnology Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran 1949635881, Iran.
在转移性癌症中克服化疗耐药性至关重要. 本综述详细介绍了分子机制和策略,如组合疗法,向治疗和免疫疗法,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗耐药性复杂化了转移性癌症的管理.
- 了解耐药机制对于有效治疗至关重要.
- 目前的化疗方法面临着重大挑战.
研究的目的:
- 为克服转移性癌症中化疗耐药性的策略提供全面的学术审查.
- 探索化疗耐药性背后的分子机制.
- 讨论当前和新兴的治疗策略.
主要方法:
- 学术出版物和临床试验的文献评论.
- 分子机制的分析,包括遗传改变,表观遗传修饰,药物代谢和生存途径.
- 检查治疗策略,如组合疗法,向疗法,免疫疗法和药物重定位.
主要成果:
- 化疗耐药性涉及遗传,表观遗传,代谢和信号通路的改变.
- 有前途的策略包括组合疗法,向药物,免疫疗法和药物重用.
- 预测生物标志物和个性化医疗方法是指导治疗的关键.
结论:
- 要对抗化疗耐药性,需要采取多方面的方法.
- 了解分子机制对于开发新型治疗策略至关重要.
- 将研究成果转化为临床实践对于改善转移性癌症治疗结果至关重要.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
相关概念视频
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Immunotherapy
